Rationale for LRRK2 inhibition in sporadic Parkinson’s disease and the LUMA trial
Objective: To summarize the rationale for LRRK2 inhibition in sporadic PD patients without LRRK2 mutations, and to describe the current design of the LUMA study,…LRRK2 Gene Mutation in Parkinson’s Disease
Objective: We aim to describe the clinical characteristics of PD linked to an LRRK2 mutation. Background: One of the most common monogenic forms of Parkinson's…LRRK2-Associated Parkinsonism With and Without In Vivo Evidence of Pathologic Alpha-Synuclein: Clinical and Biomarker Characterization
Objective: To compare clinical and biomarker features and rate of progression among LRRK2-associated parkinsonism cases with and without in vivo evidence of pathologic alpha-synuclein (asyn)…LRRK2 I1371V Mutation: Unraveling Pathogenic Mechanisms in Dopaminergic Neurons via Membrane Fluidity & Calcium Dysregulation using PD Patient iPSCs
Objective: To estimate pathogenicity of LRRK2 I1371V mutation in PD patient iPSC-derived DA-neurons & assess underlying disease mechanisms involving membrane fluidity, Ca2+ dysregulation, & Rab8A/Rab10…The natural history of Parkinson’s disease in LRRK2 G2019S carriers
Objective: To document differences between the evolution of self-reported symptoms and prodromal markers in LRRK2 G2019S carriers and non-carriers with and without Parkinson’s Disease (PD).…Genetic profile of early-onset Parkinson’s Disease patients at a movement disorders center in Brazil
Objective: This study aimed to identify the genetic landscape of early-onset Parkinson’s Disease (EOPD) in a cohort from a referral center in Brazil. Background: Parkinson’s…monogenic parkinsonism in latin america: systematic review and meta-analysis
Objective: This study aims to assess the frequency, distribution and the minimum prevalence of monogenic Parkinsonism in Latin America (LA) Background: The prevalence of monogenic…Oculomotor changes in the premotor stage of LRRK2- G2019S associated Parkinson’s disease.
Objective: To analyse oculomotor differences among idiopathic PD patients (iPD), LRRK2-G2019S PD patients (LRRK2-G2019S PD), asymptomatic carriers of LRRK2-G2019S mutation (AsG2019S), and controls, evaluated by…LRRK2 G2019S promotes astrocytic inflammatory response induced by oligomeric α-synuclein through NF-κB pathway
Objective: Analyzing the mechanism of inflammatory response induced by oligomeric α-synuclein (O-αS) in LRRK2 G2019S mutation astrocytes to provide new targets and ideas for the…Development of potent, orally bioavailable, and highly selective LRRK2 PROTAC® degrader molecules as potential disease modifying therapeutics for Parkinson’s disease
Objective: Report on the pharmacological characteristics of small molecule PROteolysis TArgeting Chimera (PROTAC) molecules designed to induce degradation of leucine rich repeat kinase 2 (LRRK2)…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 19
- Next Page »